To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
31 Newest Publications about the topic hemophiliarss
30-09-2014 | Paul J. W. Stoelinga, Walter E. Berdon, M. Michael Cohen, American Journal of Medical Genetics Part A, 2014
Simon van Creveld received both the MD and PhD degrees and had a multifaceted medical and scientific education at many hospitals and research institutes in the Netherlands, Germany, and the UK. He and his wife were the first to develop insulin for the Netherlands. His major interests were in ...
30-09-2014 | Anas M. Fathallah, Radha Ramakrishnan, Sathy V. Balu‐Iyer, Journal of Pharmaceutical Sciences, 2014
The clinical use of therapeutic proteins can be complicated by the development of anti‐product antibodies. We have previously observed that O‐phospho‐l‐serine (OPLS) reduced antibody response to FVIII in Hemophilia‐A (HA) mice. However, the mechanism underlying this observation is not clear. We ...
15-08-2014 | Hideto Matsui et al., PLoS ONE, 2014
by Hideto Matsui, Naoko Fujimoto, Noriko Sasakawa, Yasuhide Ohinata, Midori Shima, Shinya Yamanaka, Mitsuhiko Sugimoto, Akitsu Hotta Viral vectors have been used for hemophilia A gene therapy. However, due to its large size, full-length Factor VIII (FVIII) cDNA has not been successfully ...
17-10-2013 | Jun Mimuro, Hiroaki Mizukami, Midori Shima, Tadashi Matsushita, Masashi Taki, Shinji Muto, Satoshi Higasa, Michio Sa ..., Journal of Medical Virology, 2013
Abstract Pre‐existing antibodies against adeno‐associated virus (AAV), caused by natural AAV infections, interfere with recombinant AAV vector‐mediated gene transfer. We studied the prevalence of neutralizing antibodies against AAV serotypes 1, 2, 5, 8, and 9 in healthy subjects (n = 85) and ...
16-05-2013 | Gouri Shankar Pandey et al., PLoS Computational Biology, 2013
by Gouri Shankar Pandey, Chen Yanover, Tom E. Howard, Zuben E. Sauna The development of neutralizing anti-drug-antibodies to the Factor VIII protein-therapeutic is currently the most significant impediment to the effective management of hemophilia A. Common non-synonymous single nucleotide ...
01-05-2013 | Jérôme Lane; Paul J. McLaren; Lucy Dorrell; Kevin V. Shianna; Amanda Stemke; Kimberly Pelak; Stephen Moore; Johannes ..., Human Molecular Genetics, 2013
Human genetic variation contributes to differences in susceptibility to HIV-1 infection. To search for novel host resistance factors, we performed a genome-wide association study (GWAS) in hemophilia patients highly exposed to potentially contaminated factor VIII infusions. Individuals with ...
16-04-2013 | João Paulo Pimentel, Daniel Gonçalves Chaves, Ana Ruth Silva Araújo, Erbênia Maria Martins de Araújo, Liziara da Sil ..., Journal of Medical Virology, 2013
Abstract In the past decades patients with hemophilia were infected commonly by hepatitis C virus (HCV) and a significant number of patients are infected chronically. Focusing on the role of the immune system for controlling and or maintaining HCV infection, the leukocyte and cytokine profiles ...
06-02-2013 | Alisa Opar, Nature Medicine, 2013
Nature Medicine 19, 121 (2013). doi:10.1038/nm0213-121 Author: Alisa Opar
17-01-2013 | Svetla Stoilova‐McPhie, Gillian C. Lynch, Steven Ludtke, B. Montgomery Pettitt, Biopolymers, 2013
Abstract Factor VIII (FVIII) is the blood coagulation protein when defective or deficient causes for hemophilia A, a severe hereditary bleeding disorder. Activated FVIII (FVIIIa) is the co‐factor to the serine protease Factor IXa (FIXa) within the membrane‐bound Tenase complex, responsible for ...
01-01-2013 | Mark W Skinner, Molecular Therapy, 2013
Gene Therapy for Hemophilia: Addressing the Coming Challenges of Affordability and Accessibility Molecular Therapy 21, 1 (January 2013). doi:10.1038/mt.2012.272 Author: Mark W Skinner